CGT

CGTLimited DatastaleNational Heart, Lung, and Blood…Phase 1

AVL (AAV8hAAT, AAV8hAAT(AVL))

Alpha 1-Antitrypsin Deficiency · Alpha 1-Antitrypsin Deficiency

#Alpha1-AntitrypsinDeficiency#CGT#Phase1#cell-gene-therapy#CAR-T+3

Trials 10Status Recruiting

CGTLimited DatastaleNational Heart, Lung, and Blood…Phase 2

ATLCAR.CD30 T cells (ATLCAR.CD30 T cells)

Peripheral T Cell Lymphoma · CD30

#CD30#CGT#Phase2#cell-gene-therapy#CAR-T+3

Trials 7Status Recruiting

CGTLimited DatastaleNational Heart, Lung, and Blood…Phase 2

Lentiviral G1XCGD Gene Therapy (Lentiviral G1XCGD Gene Therapy)

Granulomatous Disease, Chronic, X-linked · Granulomatous Disease, Chronic, X-linked

#GranulomatousDiseaseChronicX-lin#CGT#Phase2#cell-gene-therapy#CAR-T+5

Trials 4Status Active

CGTLimited DatastaleNational Heart, Lung, and Blood…Phase 2

ATLCAR.CD30 cells (ATLCAR.CD30 cells)

Lymphoma; Lymphoma, Non-Hodgkin · CD30

#CD30#CGT#Phase2#cell-gene-therapy#CAR-T+4

Trials 2Status Recruiting

CGTLimited DatastaleNational Heart, Lung, and Blood…Phase 1

C46/CCR5/P140K Lentiviral Vector-transduced Autologous HSPCs (C46/CCR5/P140K Lentiviral Vector-transduced Autologous HSPCs)

Human Immunodeficiency Virus 1 Positive; Stage I Adult Hodgkin Lymphoma · Human Immunodeficiency Virus 1 Positive

#HumanImmunodeficiencyVirus1Posit#CGT#Phase1#cell-gene-therapy#CAR-T+3

Trials 1Status Discontinued

CGTLimited DatastaleNational Heart, Lung, and Blood…Phase 2

Gene-Corrected Macrophages administered by bronchoscopic instillation (Gene-Corrected Macrophages administered by bronchoscopic instillation)

Hereditary Pulmonary Alveolar Proteinosis · Hereditary Pulmonary Alveolar Proteinosi

#HereditaryPulmonaryAlveolarProte#CGT#Phase2#cell-gene-therapy#CAR-T+2

Trials 1Status Recruiting

CGTLimited DatastaleOttawa Heart Institute Research…Phase 3

Point-of-care genetic screening with subsequent prasugrel administration to CYP2C192 carriers (Point-of-care genetic screening with subsequent prasugrel administration to CYP2C192 carriers)

Stable Coronary Artery Disease; Acute Coronary Syndrome · Stable Coronary Artery Disease

#StableCoronaryArteryDisease#CGT#Phase3#cell-gene-therapy#CAR-T+3

Trials 1Status Active

CGTAAVLimited DatastaleYAP Therapeutics, Inc.Phase 1

AAV9-Sav-shRNA (YAP101, YAP101 (AAV9-Sav-shRNA))

Heart Failure With Reduced Ejection Fraction · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+3

Trials 1Status Recruiting

CGTLimited DatastaleNational Heart, Lung, and Blood…Phase 1

rAAV2-CB-hAAT Gene Vector (rAAV2-CB-hAAT Gene Vector)

Alpha 1-Antitrypsin Deficiency · Alpha 1-Antitrypsin Deficiency

#Alpha1-AntitrypsinDeficiency#CGT#Phase1#cell-gene-therapy#CAR-T+2

Trials 1Status Active

다음 갱신 D-5 · 마지막 9월 2일 · 방문 416 / 71,491

Biologic만FDA만

CGTLimited DatastaleNational Heart, Lung, and Blood…Phase 1

AVL (AAV8hAAT, AAV8hAAT(AVL))

Alpha 1-Antitrypsin Deficiency · Alpha 1-Antitrypsin Deficiency

#Alpha1-AntitrypsinDeficiency#CGT#Phase1#cell-gene-therapy#CAR-T+3

Trials 10Status Recruiting

CGTLimited DatastaleNational Heart, Lung, and Blood…Phase 2

ATLCAR.CD30 T cells (ATLCAR.CD30 T cells)

Peripheral T Cell Lymphoma · CD30

#CD30#CGT#Phase2#cell-gene-therapy#CAR-T+3

Trials 7Status Recruiting

CGTLimited DatastaleNational Heart, Lung, and Blood…Phase 2

Lentiviral G1XCGD Gene Therapy (Lentiviral G1XCGD Gene Therapy)

Granulomatous Disease, Chronic, X-linked · Granulomatous Disease, Chronic, X-linked

#GranulomatousDiseaseChronicX-lin#CGT#Phase2#cell-gene-therapy#CAR-T+5

Trials 4Status Active

CGTLimited DatastaleNational Heart, Lung, and Blood…Phase 2

ATLCAR.CD30 cells (ATLCAR.CD30 cells)

Lymphoma; Lymphoma, Non-Hodgkin · CD30

#CD30#CGT#Phase2#cell-gene-therapy#CAR-T+4

Trials 2Status Recruiting

CGTLimited DatastaleNational Heart, Lung, and Blood…Phase 1

C46/CCR5/P140K Lentiviral Vector-transduced Autologous HSPCs (C46/CCR5/P140K Lentiviral Vector-transduced Autologous HSPCs)

Human Immunodeficiency Virus 1 Positive; Stage I Adult Hodgkin Lymphoma · Human Immunodeficiency Virus 1 Positive

#HumanImmunodeficiencyVirus1Posit#CGT#Phase1#cell-gene-therapy#CAR-T+3

Trials 1Status Discontinued

CGTLimited DatastaleNational Heart, Lung, and Blood…Phase 2

Gene-Corrected Macrophages administered by bronchoscopic instillation (Gene-Corrected Macrophages administered by bronchoscopic instillation)

Hereditary Pulmonary Alveolar Proteinosis · Hereditary Pulmonary Alveolar Proteinosi

#HereditaryPulmonaryAlveolarProte#CGT#Phase2#cell-gene-therapy#CAR-T+2

Trials 1Status Recruiting

CGTLimited DatastaleOttawa Heart Institute Research…Phase 3

Point-of-care genetic screening with subsequent prasugrel administration to CYP2C192 carriers (Point-of-care genetic screening with subsequent prasugrel administration to CYP2C192 carriers)

Stable Coronary Artery Disease; Acute Coronary Syndrome · Stable Coronary Artery Disease

#StableCoronaryArteryDisease#CGT#Phase3#cell-gene-therapy#CAR-T+3

Trials 1Status Active

CGTAAVLimited DatastaleYAP Therapeutics, Inc.Phase 1

AAV9-Sav-shRNA (YAP101, YAP101 (AAV9-Sav-shRNA))

Heart Failure With Reduced Ejection Fraction · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+3

Trials 1Status Recruiting

CGTLimited DatastaleNational Heart, Lung, and Blood…Phase 1

rAAV2-CB-hAAT Gene Vector (rAAV2-CB-hAAT Gene Vector)

Alpha 1-Antitrypsin Deficiency · Alpha 1-Antitrypsin Deficiency

#Alpha1-AntitrypsinDeficiency#CGT#Phase1#cell-gene-therapy#CAR-T+2

Trials 1Status Active

AVL (AAV8hAAT, AAV8hAAT(AVL))

ATLCAR.CD30 T cells (ATLCAR.CD30 T cells)

Lentiviral G1XCGD Gene Therapy (Lentiviral G1XCGD Gene Therapy)

ATLCAR.CD30 cells (ATLCAR.CD30 cells)

C46/CCR5/P140K Lentiviral Vector-transduced Autologous HSPCs (C46/CCR5/P140K Lentiviral Vector-transduced Autologous HSPCs)

Gene-Corrected Macrophages administered by bronchoscopic instillation (Gene-Corrected Macrophages administered by bronchoscopic instillation)

Point-of-care genetic screening with subsequent prasugrel administration to CYP2C19*2 carriers (Point-of-care genetic screening with subsequent prasugrel administration to CYP2C19*2 carriers)

AAV9-Sav-shRNA (YAP101, YAP101 (AAV9-Sav-shRNA))

rAAV2-CB-hAAT Gene Vector (rAAV2-CB-hAAT Gene Vector)

CGT

AVL (AAV8hAAT, AAV8hAAT(AVL))

ATLCAR.CD30 T cells (ATLCAR.CD30 T cells)

Lentiviral G1XCGD Gene Therapy (Lentiviral G1XCGD Gene Therapy)

ATLCAR.CD30 cells (ATLCAR.CD30 cells)

C46/CCR5/P140K Lentiviral Vector-transduced Autologous HSPCs (C46/CCR5/P140K Lentiviral Vector-transduced Autologous HSPCs)

Gene-Corrected Macrophages administered by bronchoscopic instillation (Gene-Corrected Macrophages administered by bronchoscopic instillation)

Point-of-care genetic screening with subsequent prasugrel administration to CYP2C19*2 carriers (Point-of-care genetic screening with subsequent prasugrel administration to CYP2C19*2 carriers)

AAV9-Sav-shRNA (YAP101, YAP101 (AAV9-Sav-shRNA))

rAAV2-CB-hAAT Gene Vector (rAAV2-CB-hAAT Gene Vector)

CGT

AVL (AAV8hAAT, AAV8hAAT(AVL))

ATLCAR.CD30 T cells (ATLCAR.CD30 T cells)

Lentiviral G1XCGD Gene Therapy (Lentiviral G1XCGD Gene Therapy)

ATLCAR.CD30 cells (ATLCAR.CD30 cells)

C46/CCR5/P140K Lentiviral Vector-transduced Autologous HSPCs (C46/CCR5/P140K Lentiviral Vector-transduced Autologous HSPCs)

Gene-Corrected Macrophages administered by bronchoscopic instillation (Gene-Corrected Macrophages administered by bronchoscopic instillation)

Point-of-care genetic screening with subsequent prasugrel administration to CYP2C19*2 carriers (Point-of-care genetic screening with subsequent prasugrel administration to CYP2C19*2 carriers)

AAV9-Sav-shRNA (YAP101, YAP101 (AAV9-Sav-shRNA))

rAAV2-CB-hAAT Gene Vector (rAAV2-CB-hAAT Gene Vector)

Point-of-care genetic screening with subsequent prasugrel administration to CYP2C192 carriers (Point-of-care genetic screening with subsequent prasugrel administration to CYP2C192 carriers)

Point-of-care genetic screening with subsequent prasugrel administration to CYP2C192 carriers (Point-of-care genetic screening with subsequent prasugrel administration to CYP2C192 carriers)

Point-of-care genetic screening with subsequent prasugrel administration to CYP2C192 carriers (Point-of-care genetic screening with subsequent prasugrel administration to CYP2C192 carriers)